Docetaxel, estramustine and short term androgen withdrawal for patients with a rising PSA [prostate-specific antigen] after definitive local treatment.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Bicalutamide; Docetaxel; Estramustine; Goserelin
- Indications Prostate cancer
- Focus Adverse reactions
- 25 Jun 2018 Biomarkers information updated
- 05 Feb 2013 Planned end date changed from 1 Mar 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.
- 05 Sep 2012 Planned End Date changed from 1 Jun 2012 to 1 Mar 2013 as reported by ClinicalTrials.gov.